SHANGHAI, Jan. 4, 2023 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, announced the appointment of Dr. Mingdong Zhang to the company’s Scientific Advisory Board (SAB). Dr. Zhang will provide guidance on Pulnovo Medical’s clinical development and registration strategyand supporting the company’s global development plan. Pulnovo Medical is a medical device company […]
Other News
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on January 1, 2023 that were approved by the Compensation Committee of its Board of […]
HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive
Southlake, TX, Jan. 04, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI), today […]
Tenax Therapeutics Announces Reverse Stock Split
MORRISVILLE, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that it will be executing a reverse stock split of its outstanding shares […]
Imperative Care Announces FDA Clearance and Initial Cases of Zoom RDL, the First Stroke-Specific Radial Access Platform for Mechanical Thrombectomy
– First Patient Treated with Zoom RDL at Spectrum Health – – Newest Addition to Company’s Zoom Stroke Solution Provides an Additional Option for Achieving Intracranial Access to Treat Patients for Ischemic Stroke – CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Zoom™ […]
CARMAT Announces the First Implantation of Aeson® Within the Framework of The EFICAS Clinical Study in France
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of Aeson®, the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the first implantation of its Aeson® artificial heart within the framework of the EFICAS clinical study […]
Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
NEWTOWN, Pa., Dec. 30, 2022 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective December 27, 2022, its independent directors approved an equity award under Helius’ 2021 Inducement Plan, as a material inducement to an individual entering […]
ReCor Medical Names Lara Barghout President and Chief Executive Officer
PALO ALTO, Calif.–(BUSINESS WIRE)–ReCor Medical, Inc. (“ReCor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the appointment of Lara Barghout as President and Chief Executive Officer of ReCor. Ms. Barghout will lead the ReCor business strategy and organization in an exciting new direction: the […]
CardieX Subsidiary ATCOR Partners with Invaryant to Enable Clinical Trials with Advanced New AI Medical Technology
CardieX’s ATCOR subsidiary and Invaryant will work cohesively to conduct trials and improve patient outcomes IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ — CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes, today announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that […]
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3 study with abelacimab initiated by Anthos Therapeutics Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and […]



